Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#4560 Genetic trajectory and clonal evolution of non-functional pancreatic neuroendocrine tumours with lymph node and liver metastasis

Introduction: The systemic spread of panNETs is dominated by lymphatic reflux and portal system, exhibiting diverse patterns of metastasis without systematical genomic investigation.

Conference:

Presenting Author: Wu J

Authors: Wu J, Peng Y, Yin L, Jiang K, Li Q,

Keywords: Pan NET, Metastasis, Whole exome sequencing, Pylogenic tree,

#4513 Predictive value of different PD-L1 immunohistochemistry clones for immunotherapy efficacy in neuroendocrine tumours: A case series

Introduction: In the ZS001 clinical trial, we observed that NET patients with higher PD-L1 expression levels were more likely to benefit preferentially from immunotherapy.

Conference:

Presenting Author:

Authors: Sun Y, Zhang Q, Cao F, Huang X, Zhang P,

Keywords: neuroendocrine tumour, immunotherapy, PD-L1, SP142, 28-8, C0148, E1L3N,

#4509 Epidemiological characteristics and prognosis analysis of gastric cancer (GC) with neuroendocrine differentiation (NED)

Introduction: GC with NED exhibits distinct biological characteristics, yet research on its clinical features and prognosis remains limited.

Conference:

Presenting Author: Zhang J

Authors: Huang Z, Li J, Wang C, Shen Y, Rao S,

Keywords: gastric cancer, neuroendocrine differentiation, Epidemiological characteristics, prognosis,

#4494 Efficacy and safety of surufatinib in combination with CAPTEM for patients with advanced G2/G3 NETs: Updated results from a single-arm, phase II study

Introduction: Limited options exist for advanced G2/G3 NETs. While combined anti-angiogenic and chemotherapy has shown improved effect, the efficacy of surufatinib combined with CAPTEM for NETs remains under-explored.

Conference:

Presenting Author: Wang W

Authors: Wang W, Liu Z, Yang X, Xue Z, Wei C,

Keywords: g2/g3 net, surufatinib, captem,

#4481 Predicting peptide receptor radionuclide therapy (PRRT) response through the landscape of the immune microenvironment in neuroendocrine tumours

Introduction: Neuroendocrine tumours (NETs) often have poor prognosis upon metastasis. Peptide receptor radionuclide therapy (PRRT) is a novel treatment leveraging targeted cytotoxicity of radionuclides to efficiently address primary and metastatic tumours of NETs.

Conference:

Presenting Author: Yu J

Authors: Zeng Z, Lu M, Xie Q, Li J, Yang Z,

Keywords: peptide receptor radionuclide therapy, neuroendocrine tumour, tumour immune microenvironment, tumour response, therapeutic effect prediction,